Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The main objectives of study CAMMS32400507 is to compare the safety and efficacy of 2 annual cycles of 12 mg/day intravenous (IV) alemtuzumab to 3-times weekly subcutaneous (SC) interferon beta-1a (Rebif) in patients with active relapsing-remitting multiple sclerosis (RRMS) who have experienced at least 1 relapse during prior treatment with an interferon beta or glatiramer acetate, after having received that therapy for > 6 months
Critère d'inclusion
- Relapsing-Remitting Multiple Sclerosis